Loading...

Non-Invasive Monitoring Systems

OTCPK:NIMU
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NIMU
OTCPK
$15M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Non-Invasive Monitoring Systems, Inc., together with its subsidiaries, engages in the research, development, manufacture, and marketing of a line of motorized, non-invasive, whole body, and periodic acceleration platforms in the United States and internationally. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Non-Invasive Monitoring Systems has significant price volatility in the past 3 months.
NIMU Share Price and Events
7 Day Returns
-13.6%
OTCPK:NIMU
-0.5%
US Medical Equipment
0.8%
US Market
1 Year Returns
-36.7%
OTCPK:NIMU
14.6%
US Medical Equipment
4.8%
US Market
NIMU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Non-Invasive Monitoring Systems (NIMU) -13.6% 33.8% 28.4% -36.7% -29.6% -40.3%
US Medical Equipment -0.5% 3.1% 6.4% 14.6% 62% 103.5%
US Market 0.8% 4.3% 2.8% 4.8% 37.9% 43.5%
1 Year Return vs Industry and Market
  • NIMU underperformed the Medical Equipment industry which returned 14.6% over the past year.
  • NIMU underperformed the Market in United States of America which returned 4.8% over the past year.
Price Volatility
NIMU
Industry
5yr Volatility vs Market

NIMU Value

 Is Non-Invasive Monitoring Systems undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Non-Invasive Monitoring Systems. This is due to cash flow or dividend data being unavailable. The share price is $0.095.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Non-Invasive Monitoring Systems's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Non-Invasive Monitoring Systems's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:NIMU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in USD $-0.02
OTCPK:NIMU Share Price ** OTCPK (2019-07-15) in USD $0.1
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 40.99x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 18.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Non-Invasive Monitoring Systems.

OTCPK:NIMU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:NIMU Share Price ÷ EPS (both in USD)

= 0.1 ÷ -0.02

-5.89x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Non-Invasive Monitoring Systems is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Non-Invasive Monitoring Systems is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Non-Invasive Monitoring Systems's expected growth come at a high price?
Raw Data
OTCPK:NIMU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.89x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Non-Invasive Monitoring Systems, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Non-Invasive Monitoring Systems's assets?
Raw Data
OTCPK:NIMU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in USD $0.00
OTCPK:NIMU Share Price * OTCPK (2019-07-15) in USD $0.1
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.34x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
OTCPK:NIMU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:NIMU Share Price ÷ Book Value per Share (both in USD)

= 0.1 ÷ 0.00

120.56x

* Primary Listing of Non-Invasive Monitoring Systems.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Non-Invasive Monitoring Systems is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Non-Invasive Monitoring Systems's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Non-Invasive Monitoring Systems has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NIMU Future Performance

 How is Non-Invasive Monitoring Systems expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Non-Invasive Monitoring Systems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.9%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Non-Invasive Monitoring Systems expected to grow at an attractive rate?
  • Unable to compare Non-Invasive Monitoring Systems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Non-Invasive Monitoring Systems's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Non-Invasive Monitoring Systems's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:NIMU Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:NIMU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:NIMU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-04-30 0 -2
2019-01-31 0 -2
2018-10-31 0 -1
2018-07-31 0 0
2018-04-30 0 0 0
2018-01-31 0 0 0
2017-10-31 0 0 0
2017-07-31 0 0 0
2017-04-30 0 0 -1
2017-01-31 0 0 -1
2016-10-31 0 0 -1
2016-07-31 0 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Non-Invasive Monitoring Systems is high growth as no earnings estimate data is available.
  • Unable to determine if Non-Invasive Monitoring Systems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:NIMU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Non-Invasive Monitoring Systems Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NIMU Past Financials Data
Date (Data in USD Millions) EPS *
2019-04-30 -0.02
2019-01-31 -0.02
2018-10-31 -0.01
2018-07-31 -0.01
2018-04-30 -0.01
2018-01-31 -0.01
2017-10-31 -0.01
2017-07-31 -0.01
2017-04-30 -0.01
2017-01-31 -0.01
2016-10-31 -0.01
2016-07-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Non-Invasive Monitoring Systems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Non-Invasive Monitoring Systems's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Non-Invasive Monitoring Systems's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Non-Invasive Monitoring Systems's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Non-Invasive Monitoring Systems's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Non-Invasive Monitoring Systems has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NIMU Past Performance

  How has Non-Invasive Monitoring Systems performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Non-Invasive Monitoring Systems's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Non-Invasive Monitoring Systems does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Non-Invasive Monitoring Systems's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Non-Invasive Monitoring Systems's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Non-Invasive Monitoring Systems's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Non-Invasive Monitoring Systems Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NIMU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -1.68 0.46
2019-01-31 -1.60 0.33
2018-10-31 -0.52 0.30
2018-07-31 -0.45 0.23
2018-04-30 0.00 -0.41 0.20
2018-01-31 0.00 -0.41 0.20
2017-10-31 0.01 -0.49 0.20
2017-07-31 0.01 -0.49 0.20
2017-04-30 0.01 -0.84 0.23
2017-01-31 0.01 -0.85 0.25
2016-10-31 0.02 -0.77 0.28
2016-07-31 0.02 -0.74 0.26
2016-04-30 0.02 -0.43 0.26
2016-01-31 0.02 -0.40 0.24
2015-10-31 0.01 -0.41 0.24
2015-07-31 -0.42 0.26
2015-04-30 0.01 -0.42 0.29 0.00
2015-01-31 0.01 -0.44 0.31 0.00
2014-10-31 0.01 -0.43 0.31 0.00
2014-07-31 0.01 -0.44 0.32 0.00
2014-04-30 0.05 -0.45 0.34 0.00
2014-01-31 0.06 -0.47 0.37 0.00
2013-10-31 0.06 -0.51 0.41 0.00
2013-07-31 0.11 -0.51 0.44 0.00
2013-04-30 0.11 -0.54 0.49 0.00
2013-01-31 0.15 -0.52 0.53 0.02
2012-10-31 0.24 -0.49 0.55 0.04
2012-07-31 0.25 -0.55 0.60 0.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Non-Invasive Monitoring Systems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Non-Invasive Monitoring Systems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Non-Invasive Monitoring Systems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Non-Invasive Monitoring Systems's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Non-Invasive Monitoring Systems has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NIMU Health

 How is Non-Invasive Monitoring Systems's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Non-Invasive Monitoring Systems's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Non-Invasive Monitoring Systems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Non-Invasive Monitoring Systems has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Non-Invasive Monitoring Systems's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Non-Invasive Monitoring Systems has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Non-Invasive Monitoring Systems Company Filings, last reported 2 months ago.

OTCPK:NIMU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 0.12 0.00 0.58
2019-01-31 0.34 0.00 0.61
2018-10-31 -3.89 2.13 0.04
2018-07-31 -3.68 2.13 0.09
2018-04-30 -3.57 2.13 0.16
2018-01-31 -3.46 1.93 0.01
2017-10-31 -3.36 1.93 0.08
2017-07-31 -3.23 1.83 0.01
2017-04-30 -3.16 1.83 0.09
2017-01-31 -3.06 1.73 0.04
2016-10-31 -2.87 1.73 0.06
2016-07-31 -2.75 1.73 0.09
2016-04-30 -2.32 1.53 0.01
2016-01-31 -2.21 1.53 0.06
2015-10-31 -2.10 1.53 0.10
2015-07-31 -2.00 1.40 0.04
2015-04-30 -1.89 1.40 0.08
2015-01-31 -1.81 1.25 0.00
2014-10-31 -1.69 1.25 0.04
2014-07-31 -1.59 1.20 0.02
2014-04-30 -1.47 1.20 0.09
2014-01-31 -1.37 1.20 0.14
2013-10-31 -1.27 1.20 0.19
2013-07-31 -1.15 1.20 0.30
2013-04-30 -1.03 1.20 0.43
2013-01-31 -1.41 1.15 0.02
2012-10-31 -1.27 1.15 0.05
2012-07-31 -1.15 1.15 0.06
  • Non-Invasive Monitoring Systems has no debt.
  • Non-Invasive Monitoring Systems currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Non-Invasive Monitoring Systems has sufficient cash runway for 2 years based on current free cash flow.
  • Non-Invasive Monitoring Systems has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 6.5% each year.
X
Financial health checks
We assess Non-Invasive Monitoring Systems's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Non-Invasive Monitoring Systems has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NIMU Dividends

 What is Non-Invasive Monitoring Systems's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Non-Invasive Monitoring Systems dividends.
If you bought $2,000 of Non-Invasive Monitoring Systems shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Non-Invasive Monitoring Systems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Non-Invasive Monitoring Systems's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:NIMU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2018 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Non-Invasive Monitoring Systems has not reported any payouts.
  • Unable to verify if Non-Invasive Monitoring Systems's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Non-Invasive Monitoring Systems's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Non-Invasive Monitoring Systems has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Non-Invasive Monitoring Systems's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Non-Invasive Monitoring Systems afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Non-Invasive Monitoring Systems has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NIMU Management

 What is the CEO of Non-Invasive Monitoring Systems's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jane Hsiao
COMPENSATION $0
AGE 72
TENURE AS CEO 7.4 years
CEO Bio

Dr. Jane H. Hsiao, Ph.D., MBA, has been an Interim Chief Executive Officer of Non-Invasive Monitoring Systems Inc., since February 28, 2012 and has been its Chairman since October 2008 and its Director since October 2008. Dr. Hsiao has been the Chief Technical Officer of Opko Health, Inc. since May 2007. She serves as Investment Officer at Frost Group, LLC. She was the Founder at Innotech Laboratory in 1981 and IVAX LLC in 1986. She served as the President of Ophthalmic Technologies, Inc. Dr. Hsiao served as the Vice Chairman-Technical Affairs and Chief Technical Officer of IVAX, from 1995 until January 2006. She serves as a Director of Acuity Pharmaceuticals Inc., Fabrus, Inc., Cocrystal Discovery, Inc. and Froptix Corporation. She has been the Vice Chairman of Opko Health Inc. since May 2007. She has been the Chairman of; and Cellular Technical Services Co. Inc. since September 5, 2007. She served as the Chairman of SafeStitch Medical, Inc. ince September 5, 2007. She is Chairman, Chief Executive Officer, President of DVM Pharmaceuticals Inc. and Director of IVAX Diagnostics Inc at IVAX LLC. She has been a Director of Protalix Ltd. since August 2006; Opko Health Inc. since 2007; OPKO Biologics since May 2007 and Cellular Technical Services Company, Inc. since September 5, 2007. She served as the Chief Executive Officer and President of DVM Pharmaceuticals Inc., IVAX’ veterinary products subsidiary of IVAX LLC from March 1998 to 2006. Dr. Hsiao also served as Chairman, CEO and President of IVX Animal Health from 1998 until 2006. From 1992 to February 1995, she served as IVAX LLC‘s Chief Regulatory Officer and Assistant to the Chairman and Vice President of Quality Assurance and Compliance of IVAX Research, Inc. From 1987 to 1992, she served as a Vice President of Quality Assurance, Quality Control and Regulatory Affairs at IVAX Research, Inc. She served as the Chairman of DVM Pharmaceuticals Inc. from March 1998 to 2006. She served as a Vice Chairman of IVX Animal Health. She served as a Vice Chairman-Technical Affairs and Director of IVAX LLC from 1995 to January 2006, when Teva acquired IVAX. Dr. Hsiao has been a Director of Cocrystal Pharma, Inc. since January 2, 2014. She has been a Director of TransEnterix, Inc. since 2005. She served as a Director of Medical Ventures Corp. and its Independent Director since July 1, 2008. She served as a Director of SafeStitch Medical, Inc. since April 2005. She served as a Director of Protalix Biotherapeutics Ltd. from December 31, 2006 to December 2007; IVAX Pharmaceuticals s.r.o. (Ivax-CR AS); eXegenics Inc. since February 9, 2007; Orthodontix Inc., since January 3, 2007; IVAX Corp. since 1995 and IVAX Diagnostics Inc., from 2001 to April 2006. She is a Director of Tissuetech, Inc. She served as Director of Prolor & Sorrento Therapeutics, Inc. since January 2010. Dr. Hsiao has background in building and growing companies in the pharmaceutical and medical device industry and has strong technical expertise, as well as her senior management experience and extensive Board service. Her broad experience in many biotechnology and life science companies gives her a keen understanding and appreciation of the many regulatory and developmental issues confronting medical device, pharmaceutical and biotechnology companies. Additionally, Dr. Hsiao serves as a Director to Neovasc, Inc. since July l, 2008. Dr. Hsiao received a B.S. degree in Pharmacy from the National Taiwan University and a Ph.D. degree in Pharmaceutical Chemistry and Medicinal Chemistry from the University of Illinois, Chicago in 1973. She also holds an M.B.A. degree.

CEO Compensation
  • Insufficient data for Jane to compare compensation growth.
  • Jane's remuneration is lower than average for companies of similar size in United States of America.
Management Team

Jane Hsiao

TITLE
Chairman & Interim CEO
AGE
72
TENURE
7.4 yrs

Jim Martin

TITLE
CFO & Treasurer
AGE
52
TENURE
8.5 yrs

Joshua Weingard

TITLE
Secretary
AGE
46
Board of Directors Tenure

Average tenure and age of the Non-Invasive Monitoring Systems board of directors in years:

10.8
Average Tenure
72
Average Age
  • The average tenure for the Non-Invasive Monitoring Systems board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jane Hsiao

TITLE
Chairman & Interim CEO
AGE
72
TENURE
10.8 yrs

Subbarao Uppaluri

TITLE
Director
COMPENSATION
$5K
AGE
70
TENURE
10.8 yrs

Steve Rubin

TITLE
Director
COMPENSATION
$5K
AGE
59
TENURE
10.8 yrs

Marvin Sackner

TITLE
Director
AGE
87
TENURE
29.7 yrs

Morton Robinson

TITLE
Director
COMPENSATION
$3K
AGE
87
TENURE
29.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Jan 19 Buy Jane Hsiao Individual 21. Dec 18 21. Dec 18 6,352,074 $0.07 $100,000
X
Management checks
We assess Non-Invasive Monitoring Systems's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Non-Invasive Monitoring Systems has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NIMU News

Simply Wall St News

NIMU Company Info

Description

Non-Invasive Monitoring Systems, Inc., together with its subsidiaries, engages in the research, development, manufacture, and marketing of a line of motorized, non-invasive, whole body, and periodic acceleration platforms in the United States and internationally. It offers Exer-Rest line of acceleration therapeutic platforms, including the Exer-Rest AT3800 and the Exer-Rest AT4700 models, which are whole body periodic acceleration therapeutic devices to healthy individuals, as well as for physicians and their patients. The company was incorporated in 1980 and is headquartered in Miami, Florida.

Details
Name: Non-Invasive Monitoring Systems, Inc.
NIMU
Exchange: OTCPK
Founded: 1980
$14,707,012
154,810,655
Website: http://www.nims-inc.com
Address: Non-Invasive Monitoring Systems, Inc.
4400 Biscayne Boulevard,
Suite 180,
Miami,
Florida, 33137,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK NIMU Common Stock Pink Sheets LLC US USD 02. Feb 1984
Number of employees
Current staff
Staff numbers
0
Non-Invasive Monitoring Systems employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 23:41
End of day share price update: 2019/07/15 00:00
Last earnings filing: 2019/06/14
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.